You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The financing will go toward driving adoption of the company's technology, which can distinguish bacterial infections from viral ones, and other purposes.
The company said it will use the proceeds to develop new liquid biopsy tests to predict drug response in cancer patients.
The financing will be used to further development of a handheld device, which is being designed to be used with a high-sensitivity troponin assay.
The firm's microfluidic diagnostic system uses phenotypic bacteria growth analysis to enable rapid antibiotic testing and treatment of sepsis patients.
The funding will go toward expanding the firm's product line and increasing access to its testing services. MyLab Box has raised $2.1 million in total.
The company’s software-as-a-service and sequencing and molecular analysis revenues grew, and the firm narrowed its loss from a year ago.
VolitionRx has reached a definitive agreement with an investor for the placement of 5 million shares of the firm's stock at $1.80 per share.
The San Diego-based company is ramping up efforts to market its handheld molecular influenza test in anticipation of the upcoming flu season.
The firm has reached a deal with certain investors for the purchase of units comprising OncoCyte common shares and warrants to purchase shares.
The company said it plans to use the financing to increase adoption of its MammaPrint BluePrint next-generation sequencing-based test kit for breast cancer.